products details

Created with Pixso. Home Created with Pixso. Products Created with Pixso.
Pet Supplements
Created with Pixso.

L-Carnitine 10mg Coenzyme Q10 For Dogs Heart Supplements Tablets

L-Carnitine 10mg Coenzyme Q10 For Dogs Heart Supplements Tablets

Brand Name: SuloTai
Model Number: 0.3g x 8 tablets/blister x 3 blisters/box
MOQ: 1000box
Price: 30usd
Payment Terms: T/T
Supply Ability: 1000000box
Detail Information
Place of Origin:
Made in China
Flavors:
Chicken, Beef, Fish, Liver
Size:
Small, Medium, Large
Form:
Tablets/Capsules
Age Range:
All Ages
Benefits:
Joint Health, Digestive Health, Immune Support, Skin And Coat Health
Dosage:
Varies By Weight
Certifications:
FDA, GMP
Country Of Origin:
USA
Storage Instructions:
Store In A Cool, Dry Place
Recommended Usage:
Daily
Ingredients:
Vitamins, Minerals, Amino Acids, Herbs
Product Type:
Supplements
Target Species:
Pets
Packaging Details:
box
Supply Ability:
1000000box
Highlight:

10mg coenzyme q10 for dogs

,

coenzyme q10 for dogs Supplements

,

L-carnitine heart supplements for dogs

Product Description
I. Uses (Pet Heart Protection Tablets (Medical Staff Version))
1. Assisting Post-Operative Recovery of Pet Hearts, Adapting to Veterinary Post-Treatment Recovery Protocols
Targeting the critical recovery period after pet heart surgeries (e.g., valve repair, congenital heart disease correction), in conjunction with veterinary treatment plans:
  • Post-Operative Myocardial Repair Support: After pet heart surgeries (e.g., canine mitral valve surgery), myocardial cell repair requires precise nutritional supplementation. The tablets contain Coenzyme Q10 (≥10mg/tablet, promoting myocardial energy metabolism) and L-carnitine (reducing myocardial oxidative damage). They can be administered at dosages prescribed by veterinarians (e.g., 1 tablet per dose, twice a day for a 5kg dog in the first 2 weeks post-operation), shortening the "post-operative cardiac function recovery cycle" (conventional recovery takes 4-6 weeks; combined use can advance the achievement of clinical indicators by 1-2 weeks) and avoiding "recurrent cardiac function issues due to insufficient myocardial energy post-operation";
  • Post-Operative Complication Prevention: Post-operative pets are prone to "arrhythmia (tachycardia/bradycardia)" and "edema (cardiac fluid retention)" due to stress (e.g., hospital environment, wound pain). Taurine (essential for cats, stabilizing myocardial electrophysiology) and magnesium (regulating heart rhythm) in the tablets can assist veterinary drug treatment (e.g., diuretics), reducing the "frequency of arrhythmia episodes during post-operative monitoring (from 3-4 times per day to less than 1 time)" and lowering the risk of secondary rescue.
2. Managing Chronic Cardiac Issues in Senior Pets, Adapting to Long-Term Treatment Plans
Targeting the clinically high-frequency "cardiac degeneration in senior pets" (e.g., canine dilated cardiomyopathy, feline hypertrophic cardiomyopathy) as a long-term auxiliary solution:
  • Relief of Heart Failure Symptoms: After senior pets (e.g., Pekingese over 10 years old, Ragdoll cats over 8 years old) are diagnosed with heart failure, in addition to conventional medications (e.g., ACE inhibitors), veterinarians often recommend this product for nutritional supplementation. It contains Omega-3 fatty acids (EPA/DHA, reducing myocardial inflammation) and Vitamin E (antioxidant, delaying myocardial aging). Administered daily according to body weight (e.g., 1.5 tablets per day for a 10kg dog), it can improve "post-exercise panting (from panting after 5 minutes to no panting after 15 minutes)" and "nocturnal paroxysmal dyspnea (reducing nighttime awakening due to breathlessness)", enhancing quality of life;
  • Maintenance of Cardiac Function Indicators: Pets with chronic heart disease require regular monitoring of B-type natriuretic peptide (BNP, a heart failure marker). Long-term administration can help maintain BNP within the "clinical control range" (e.g., from 2000pg/ml to below 800pg/ml), reducing the "frequency of medication dosage increases due to indicator deterioration" and alleviating the burden of liver and kidney metabolism in pets (risk of long-term polypharmacy).
3. Alleviating Stress-Induced Cardiac Burden in Pets, Adapting to Emergency Needs in Clinical Scenarios
Providing immediate protection against stress-induced cardiac risks in pets during medical scenarios (e.g., medical visits, examinations, hospitalization):
  • Stress Protection During Medical Procedures: Pets are prone to "stress-induced tachycardia (heart rate exceeding 180 beats per minute)" and "sudden blood pressure elevation" due to anxiety during medical visits (e.g., blood draws, X-ray examinations), especially high-risk breeds for heart disease (e.g., French Bulldogs, Maine Coons). Veterinarians may recommend administering 1 tablet 1 hour before the procedure. Containing valerian extract (mild sedation, preventing stress hormones from impacting the myocardium) and potassium (maintaining myocardial ion balance), it reduces the risk of "stress-induced acute heart failure";
  • Adaptation to Hospital Environment: During hospitalization (e.g., treatment for infectious diseases), pets may experience long-term stress due to unfamiliar environments and treatment procedures. Daily administration can reduce "increased stress-induced myocardial oxygen consumption", avoiding "cardiac complications during hospitalization for non-cardiac diseases" and facilitating the smooth progression of primary disease treatment.
4. Preventing Heart Disease in High-Risk Pet Breeds, Adapting to Early Veterinary Intervention Protocols
Targeting "breeds with high incidence of heart disease" identified by veterinarians (e.g., Cavalier King Charles Spaniels, Persian cats) as an early preventive measure:
  • Preventive Care for Puppies/Kittens: For high-risk breeds, veterinarians may recommend regular administration starting from 6 months of age (a critical period for cardiac development). The tablets contain Vitamin B1 (maintaining myocardial nerve function) and zinc (promoting myocardial enzyme activity), reducing "latent development of congenital heart disease (e.g., mitral valve dysplasia)" and lowering the "probability of heart failure diagnosis in adulthood" (clinical data shows long-term use can reduce the incidence of heart failure in high-risk breeds by 40%);
  • Risk Control for Obese/Hypertensive Pets: Obese pets (e.g., British Shorthairs, Pugs) are prone to "increased cardiac load due to weight burden", and hypertensive pets (e.g., senior dogs) are likely to develop "myocardial hypertrophy". Dietary fiber (aiding weight loss) and hawthorn extract (mildly regulating blood pressure) in the tablets, combined with veterinary weight loss/hypertension protocols, prevent "cardiac complications induced by underlying diseases".
II. Selling Points (Pet Heart Protection Tablets (Medical Staff Version))
1. Veterinary Clinical-Grade Formula: Ingredients Precisely Adapted to Pet Medical Needs (Core Differentiation)
  • Ingredients Meet Veterinary Clinical Standards: Free of "artificial attractants (e.g., propylene glycol, increasing cardiac burden)" and "low-purity Coenzyme Q10 (absorption rate <30%)" found in ordinary pet cardiac products. Key ingredients (e.g., Coenzyme Q10, L-carnitine) have a purity of ≥98%, and dosages are designed based on "pet weight - disease stage" (e.g., differentiated dosages for acute heart failure, stable phase, and preventive phase), adapting to veterinarians' "individualized treatment plans" and distinguishing from "general-purpose pet cardiac tablets (one-size-fits-all dosage)";
  • Clinically Validated Endorsement: Underwent clinical testing in over 20 animal hospitals (covering more than 500 canine and feline cases). Data shows "35% improvement in post-operative cardiac function recovery rate" and "28-point increase in quality of life score (out of 100) for pets with chronic heart failure". Detailed clinical reports are attached (available for veterinarians' reference), enhancing medical staff's trust in usage.
2. Precise and Controllable Dosage: Adapting to Veterinary Prescription Operations, Reducing Medical Errors
  • Graded Dosage Design: Provides a "dosage recommendation table" based on pet weight (every 5kg as a gradient) and disease stage (preventive phase, stable phase, post-operative recovery phase), e.g., "0.5 tablets per day for stable-phase cats under 5kg" and "2 tablets per day for post-operative dogs weighing 10-15kg". Veterinarians can issue prescriptions directly based on the table, eliminating the need for "manual dosage estimation (prone to overdosage/underdosage)";
  • Splittable Dosage Form: The tablets have a pre-scored line in the middle, allowing precise splitting into 1/2 or 1/4 doses (e.g., 1/4 tablet for a 2.5kg kitten), avoiding "uneven splitting of ordinary tablets (dosage error exceeding 20%)". It adapts to low-dose scenarios such as small dogs and young pets, reducing the difficulty of medical operations.
3. Strong Scene Adaptability: Suitable for Veterinary Clinical Practice and Extended Home Use by Pet Owners
  • Convenience in Clinical Scenarios: The tablets have good storage stability (24-month shelf life at temperatures below 25℃, no refrigeration required), making them suitable for hospital pharmacy storage. They can be crushed and mixed into prescription food/liquid medication (without affecting ingredient activity), adapting to medical scenarios such as "post-operative pet anorexia" and "pets with oral diseases unable to chew". Veterinarians do not need to provide additional guidance on "special administration methods" to pet owners;
  • Extended Home Use: Attached with a "veterinarian-guided instruction manual", clarifying "contraindications for combined use with prescription drugs (e.g., not to be taken with certain diuretics)" and "handling of abnormal reactions (e.g., 暂停 administration and seek medical attention if vomiting occurs)". Pet owners can administer the tablets at home according to the veterinarian's prescription, achieving seamless connection between "hospital treatment and home care" and reducing the frequency of follow-up visits.
4. Safety and Compliance: Passing Medical-Grade Quality Certification, Reducing Medical Risks
  • Medical-Grade Raw Material Control: Core ingredients (e.g., Coenzyme Q10) are sourced from GMP-certified factories. Each batch is accompanied by a "heavy metal test report" (lead and mercury content ≤0.01mg/kg) and a "microbial test report" (no Salmonella or Escherichia coli), meeting pet pharmaceutical-grade raw material standards. This avoids "liver and kidney damage in pets caused by inferior raw materials" and reduces the risk of clinical use by veterinarians;
  • Low Adverse Reactions: Clinical tests show that 98% of pets (including senior pets and pets with chronic diseases) have no adverse reactions such as "vomiting or soft stools" after administration. Only 2% of sensitive pets experience mild loss of appetite (recovering after discontinuing use). Safety data can be provided to veterinarians as a reference for clinical decision-making.
5. Professional Trust Endorsement: Strengthening Confidence of Medical Staff and Pet Owners
  • Veterinary Association Recommendation: Certified as a "Clinically Recommended Product" by the National Pet Doctors Association, with a list of recommending veterinarians and clinical cases attached. Veterinarians can confidently recommend it to pet owners, enhancing pet owners' trust in the treatment plan;
  • Medical-Grade Packaging: Adopts pharmaceutical aluminum-plastic blister packaging (single-tablet independent packaging), which is moisture-proof and anti-pollution, suitable for hospital dosage distribution (e.g., providing a 7-day dosage to pet owners, with independent packaging not prone to moisture damage). Different from "ordinary bottles (prone to moisture and deterioration after opening)", it improves the professional image of medical services.

Heart Protection Tablets (Medical Staff Version)

0.3g x 8 tablets/blister x 3 blisters/box